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Background and aims: Statin utilization and lipid goal achievement were estimated in a large sample of
Italian patients at high/very-high cardiovascular (CV) risk.
Methods: Patients aged 18 years with a valid low-density lipoprotein cholesterol (LDL-C) measurement
in 2015 were selected from the IMS Health Real World Data database; non-high-density lipoprotein
cholesterol (non-HDL-C) was assessed in those with available total cholesterol measurements. Index
dates were defined as the last valid lipid measurement in 2015. Patients were hierarchically classified
into mutually exclusive risk categories: heterozygous familial hypercholesterolemia (primary and sec-
ondary prevention), atherosclerotic CV disease (including recent acute coronary syndrome [ACS], chronic
coronary heart disease, stroke, and peripheral arterial disease), and diabetes mellitus (DM) alone. Statin
and non-statin lipid-modifying therapy (LMT) use, and European Society of Cardiology (ESC)/European
Atherosclerosis Society (EAS) guideline-recommended goal attainment, were assessed.
Results: Among 66,158 patients meeting selection criteria, the overall rate of LMT prescriptions was
53.3%, including 7.7% on high-intensity statin therapy. Statin use was highest for recent ACS and lowest
for DM alone. LDL-C goal attainment was 16.0% for <1.8mmol/l and 45.0% for <2.5mmol/l; 24.3% reached
non-HDL-C <2.6mmol/l and 52.2% were at <3.3mmol/l. Goal achievement was greatest with high-
intensity statin use.
Conclusions: Statin use in this cohort was consistent with previous reports in Italian patients at high/
very-high CV risk, and low relative to statin use in other European countries. The low rate of ESC/EAS
lipid goal attainment observed was consistent with outcomes of other European studies.
© 2018 The Authors. Published by Elsevier B.V. This is an open access article under the CC BY-NC-ND
license (http://creativecommons.org/licenses/by-nc-nd/4.0/).1. Introduction
Despite recent decreases in cardiovascular (CV) mortality, CV
disease (CVD) continues to account for most deaths in Italy (~38%),Interna e Specialita Mediche,
erto I Viale del Policlinico, 155
ca).
B.V. This is an open access article uwith ischemic heart disease and stroke, in particular, remaining
major public health issues (ranking high among causes of years of
life lost, causing 6% and 3%, respectively, of the total) [1,2]. Age-
standardized 2012 mortality rates for coronary heart disease
(CHD) in Italy were 148.0 per 100,000 for men and 82.7 per 100,000
for women [1]. Decreasing low-density lipoprotein cholesterol
(LDL-C) with statin therapy has been demonstrated to reduce
mortality and improve CV outcomes significantly, both among
populations with established CVD and in primary preventionnder the CC BY-NC-ND license (http://creativecommons.org/licenses/by-nc-nd/4.0/).
M. Arca et al. / Atherosclerosis 271 (2018) 120e127 121groups [3e7]. Moreover, many Italians have high lipid levels; e.g., in
one observational study representative of the general Italian adult
population aged 40e79, the proportion with hypercholesterolemia
was 55.6% [8]. Statins offer demonstrated benefits: randomized
controlled trials show that each 1mmol/l (39mg/dl) reduction in
LDL-C effects a consistent ~22% reduction in CV events across
varying CV risk profiles, clinical and demographic characteristics,
and baseline LDL-C levels [3]. Furthermore, CV outcomes benefits
are greater with high- versus moderate-intensity statin therapy
[9e11], and statins have been widely shown to be well tolerated
and safe [3,12,13]. Nevertheless, in Europe, including Italy, statins
remain markedly underutilized relative to other countries and re-
gions, and LDL-C reductions fall notably short of clinical guidelines
[14e16].
Statins are recommended by both the European Society of
Cardiology (ESC)/European Atherosclerosis Society (EAS) and
Italian guidelines as first-line pharmacological treatment of hy-
percholesterolemia. When the present study was conducted, the
2011 ESC/EAS cholesterol treatment guidelines were in place,
which recommended that patients with very-high CV risk
(defined as established CVD, type 1 or 2 diabetes mellitus [DM]
with end organ damage, moderate-to-severe chronic kidney
disease [CKD], or a 10-year Systematic COronary Risk Evaluation
[SCORE] risk 10%) achieve an LDL-C treatment goal of
<1.8mmol/l (<70mg/dl) or, when this goal cannot be achieved, a
50% reduction from baseline LDL-C [17]. For patients with high
CV risk (defined as markedly elevated single risk factors, or a 10-
year risk SCORE 5% to <10%) the LDL-C treatment goal was
<2.5mmol/l (<100mg/dl) [17]. To estimate CV risk, the 2011 ESC/
EAS guidelines also recommended measurement of non-high-
density lipoprotein cholesterol (non-HDL-C), particularly in pa-
tients with DM, metabolic syndrome, or CKD [17], with non-HDL-
C targets of <2.6mmol/l and <3.3mmol/l (<100mg/dl and
<127mg/dl) for patients at very-high and high CV risk, respec-
tively. Since the completion of the data extraction for the present
study, updated (2016) ESC/EAS guidelines have been released,
with minimal differences regarding statin recommendations and
related thresholds [18]. The ESC/EAS guidelines affirm that
thresholds can be achieved with statin monotherapy in the ma-
jority of patients with an elevated CV risk. The Italian national
guidelines are also closely aligned, recommending statins for
individuals who have already experienced a CV event, including
peripheral arterial disease (PAD), with an LDL-C goal of <70mg/
dl, and for those with familial dyslipidemias, DM, CKD, or a 10-
year risk SCORE 5%, with an LDL-C goal of <100mg/dl [19].
Despite demonstrated statin benefits, the CV burden in Italy
remains high, and the literature describing statin utilization and
lipid goal attainment in Italian patients with established CVD is
limited [20e22]. The present study assessed real-world evidence of
lipid-modifying therapy (LMT) utilization in Italy in 2015 compared
with the 2011 ESC/EAS guidelines in place at the time. Using de-
identified data from a large sample of primary care electronic
medical records (EMRs), LMT utilization and achievement of LDL-C
and non-HDL-C ESC/EAS guideline targets are described, within
each of the following indications: heterozygous familial hyper-
cholesterolemia (HeFH); atherosclerotic cardiovascular disease
(ASCVD), including recent acute coronary syndrome (ACS), chronic
CHD, stroke and PAD; and DM.
2. Patients and methods
2.1. Database and cohort selection
A retrospective observational study of a cross-section of Italian
patients at high or very-high CV risk was conducted using the IMSHealth Real World Database. This database included anonymized
EMRs of ~750,000 patients from routine clinical practices of
approximately 700 Italian general practitioners (GPs) in 2015. De-
identified data pertain to EMRs completed by physicians during
patient office visits. This primary care database represents over 2%
of the Italian adult population. Validation studies, comparing the
information in this database with that available from the Italian
Office of National Statistics and other sources in Italy, have
demonstrated that the database population is representative of the
general population in Italy with respect to age and sex distribution,
and the prevalence of chronic conditions such as hypertension,
chronic obstructive pulmonary disease, and DM. Prescription vol-
ume for selected drug classes, including non-steroidal anti-in-
flammatory drugs, and psychotropic, alimentary tract, and
cardiovascular medicines, is also comparable to national statistic
usage [23].
Inclusion criteria were: a valid LDL-C measurement in 2015 (the
last 2015 LDL-C measurement was designated as the index date);
18 years of age; and 1 high/very-high CV risk condition as
defined by the 2011 ESC/EAS guidelines [17]. At least 2 years of
continuous enrollment in the database before the index date were
required to classify patients, and to assess current LMT and prior
LMT for patients not currently prescribed treatment.
2.2. Determination of ASCVD and non-ASCVD categories
Six high/very-high CV risk mutually exclusive groups were
defined in the pre-index period, using the following hierarchy: 1)
clinically diagnosed HeFH (defined as 4 points on the Dutch Lipid
Clinic Network diagnostic criteria [DLCNDC; Supplemental Table 1],
as a reflection of the 87.6% of patients with DLCNDC scores 4 to
<6); [24] 2) recent ACS (myocardial infarction [MI] or unstable
angina requiring hospitalization within the 12 months before the
index date); 3) chronic CHD (history of MI, stable or unstable
angina, coronary revascularization, or another CHD diagnosis); 4)
stroke (including transient ischemic attack); 5) PAD (peripheral
vascular disease by non-coronary atherosclerotic disease, abdom-
inal aortic aneurysm, and carotid artery stenosis); and 6) DM (all
severities, including both type 1 DM and type 2 DM). Groups were
identified using GP-recorded diagnosis codes per the International
Classification of Diseases, Ninth Revision (ICD-9; Supplemental
Table 2).
Patients with the hierarchical conditions recent ACS, chronic
CHD, stroke, and PAD are jointly referred to as ‘ASCVD’, while data
for patients with DM alone (referred to as ‘non-ASCVD’) and pa-
tients with HeFH (comprising both HeFH patients under primary
prevention and HeFH patients under secondary CV prevention), are
presented separately.
2.3. Determination of LMT treatment
Current LMT treatment was assumed if, for a recorded pre-
scription of any length, there was evidence of supply on or within
30 days before the index date. Patients not “currently treated” but
with evidence of supply for an LMT prescription >30 days before
the index date were considered to have a history of LMT treatment
(Fig.1). Patients not currently treated andwithout history of LMTon
the index date or during the 2 years before the index date were
considered to have no evidence of LMT treatment.
LMTs were classified as statin or non-statin LMT. Statin therapy,
alone or in combination with non-statin LMT, was stratified as
either high intensity (atorvastatin 40mge80mg or rosuvastatin
20mge40mg) or low to moderate intensity (all other statins and
doses). Non-statin LMT included ezetimibe, niacin (nicotinic acid),
fibrates (gemfibrozil, fenofibrate, fenofibric acid, ciprofibrate, and
Fig. 1. Lipid-modifying therapy prescription status as of the index date.
Reproduced with permission from Steen et al. [50]. Blue bars representing scenarios A and B (medication supply via recorded Rx on or within 30 days prior to the index date) define
the patient as being treated as of the index date. The red bar representing scenario C (medication supply via recorded Rx more than 30 days prior to the index date) defines the
patient as not being treated as of the index date. Rx, prescription. (For interpretation of the references to colour in this figure legend, the reader is referred to the Web version of this
article.)
Fig. 2. Italian cohort selection.
ASCVD, atherosclerotic cardiovascular disease; CV, cardiovascular; DM, diabetes mel-
litus; HeFH, heterozygous familial hypercholesterolemia; LDL-C, low-density lipopro-
tein cholesterol.
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velam, and colestipol).
2.4. Determination of LDL-C and non-HDL-C levels
Achievement of 2011 ESC/EAS lipid goals for high and very-
high CV risk; i.e., LDL-C <2.5mmol/l and <1.8mmol/l, and non-
HDL-C <2.6 mmol/l and <3.3 mmol/l, respectively, was assessed.
The current LMT and lipid values were assessed concurrently (i.e.,
overlapping with or actually on the index date), to ensure that
lipid levels best reflected the impact of the current treatment
regimen.
2.5. Statistical analysis
Descriptive statistical analyses were conducted for this study.
Demographic, clinical, and medication characteristics, LMT utili-
zation, and achieved lipid levels were described via proportions
and mean± standard deviation (SD), as appropriate. All analyses
were conducted with SAS® V.9.4.
3. Results
The inclusion criteria were met by 66,158 patients (Fig. 2),
comprising 2081 (3.1%) with clinically diagnosed HeFH, 36,120
(54.6%) with ASCVD, and 27,957 (42.3%) with DM alone. Among the
hierarchical ASCVD subcategories, recent ACSwas identified for 736
patients (1.1%), chronic CHD for 19,622 (29.7%), stroke for 9721
(14.7%), and PAD for 6041 (9.1%). The mean age was 70.7 years and
59.5% were male (Table 1).
3.1. LMT utilization in 2015
In total, 53.3% of patients were prescribed LMT, and 51.0% were
prescribed statin therapy (7.7% high-intensity statins, 43.3% low-to-
moderate intensity statins, and 2.3% non-statin LMT; Table 2).
Statins were mostly prescribed as monotherapy (96.7% with high-
intensity and 93.1% low-to-moderate intensity statin). Approxi-
mately 2.8% of patients on high-intensity and 6.5% on low-to-
moderate intensity statins had concomitant ezetimibe
prescriptions.
3.1.1. ASCVD population
Approximately 61.1% of patients with ASCVD were prescribed
LMT and 58.9% were prescribed statins. Among the ASCVD hierar-
chical risk categories, patients with a recent ACS had the highestprescription rates for any statin and for high-intensity statin, fol-
lowed by CHD, stroke, and PAD (Table 2).
Among patients with ASCVD treated with non-statin LMT
monotherapy, ezetimibe was most commonly prescribed among
patients with recent ACS, and decreasingly so for patients with
CHD, stroke, and PAD (Table 2). LMT non-treatment rates are also
shown in Table 2.
3.1.2. DM alone (non-ASCVD population)
Among patients with DM alone, 42.4% were prescribed LMT and
39.9% were prescribed statins. Only 2.4% had prescriptions for high-
intensity statins, and only 24.2% of those treated with non-statin
LMT received ezetimibe (Table 2). In total, 57.5% had no evidence
of LMT use on the index date, of whom 68.3% also had no indication
of having had prescriptions for LMT within the 2 years before.
3.1.3. HeFH patients
In total, 64.7% of HeFH patients were prescribed LMT and 62.5%
Table 1
Baseline characteristics for the overall study cohort and hierarchical CV risk subgroups.
Total cohort
N¼ 66,158
ASCVD
n¼ 36,120
DM alone
n¼ 27,957
HeFHa
n¼ 2081
Recent ACS
n¼ 736
Chronic CHD
n¼ 19,622
Stroke
n¼ 9721
PAD
n¼ 6041
Demographic characteristics
Age, years, mean (SD) 70.7
(11.3)
67.4 (12.8) 72.8
(10.3)
73.4
(9.4)
72.7 (10.4) 68.4
(11.9)
63.9 (12.6)
Male, % 59.5 41.7 49.2 64.7 62.1 62.9 76.0
Prevalent CV risk conditions, %
HeFH 3.1 0 0 0 0 0 100
Recent ACS 1.1 100 0 0 0 0 0.3
Chronic CHD 30.7 57.6 100 0 0 0 13.9
Stroke/TIA 19.5 10.7 14.7 100 0 0 9.7
PAD 15.8 11.1 14.4 13.7 100 0 8.5
DM 62.5 28.0 39.0 33.5 31.9 100 17.5
Comorbidities of interest, %
Hypertension 76.3 69.4 76.5 81.7 76.1 75.6 60.7
History of CHFb 5.9 7.1 10.8 4.3 4.7 3.5 2.5
Dementiab 1.5 0.5 1.8 1.6 1.7 1.3 1.0
COPDb 16.7 16.6 20.6 17.8 21.7 12.9 11.0
Musculoskeletal pain 89.3 84.1 90.1 91.7 93.3 87.3 88.0
Moderate/severe liver diseaseb 0.3 0.4 0.2 0.2 0.4 0.4 0
Concomitant medications, %
Beta-blockers 50.3 80.0 77.2 41.6 38.0 37.5 36.3
ACEIs/ARBs 77.1 83.8 86.0 77.1 71.8 73.3 56.6
Clopidogrel 13.2 31.3 32.3 8.9 7.9 2.4 5.7
ACEI, angiotensin-converting enzyme inhibitor; ACS, acute coronary syndrome; ARB, angiotensin II receptor blocker; ASCVD; atherosclerotic cardiovascular disease; CHD,
coronary heart disease; CHF, congestive heart failure; COPD, chronic obstructive pulmonary disease; CV, cardiovascular; DM, diabetes mellitus; HeFH, heterozygous familial
hypercholesterolemia; PAD, peripheral arterial disease; SD, standard deviation; TIA, transient ischemic attack.
a HeFH includes primary prevention HeFH patients (no ASCVD) and secondary prevention HeFH patients (with ASCVD).
b Based on Quan-Charlson comorbidity scale components.
Table 2
Use of LMT overall and by hierarchical disease categories.
% Total cohort
N¼ 66,158
ASCVD
n¼ 36,120
DM alone
n¼ 27,957
HeFHa
n¼ 2081
Recent ACS
n¼ 736
Chronic CHD
n¼ 19,622
Stroke
n¼ 9721
PAD
n¼ 6041
High-intensity statin 7.7 56.1 15.9 5.5 3.6 2.4 6.7
Monotherapy 96.7 97.8 96.3 97.9 95.8 97 95.7
Plus ezetimibe 2.8 1.9 3.3 1.7 1.9 2.4 2.9
Plus other non-statin LMT 0.5 0.2 0.4 0.4 2.3 0.6 1.4
Low-to-moderate intensity statin 43.3 26.6 49.8 49.4 36.7 37.5 55.8
Monotherapy 93.1 87.2 90.5 94.4 95.3 95.3 87.2
Plus ezetimibe 6.5 12.2 9.3 5.2 4.4 4.2 12.7
Plus other non-statin LMT 0.4 0.5 0.3 0.3 0.3 0.5 0.1
Nonstatin LMT only 2.3 1.9 2.5 2.2 1.6 2.5 2.2
Ezetimibe 41.0 92.9 58.5 45.2 35.7 24.2 91.3
Other LMT 59.0 7.1 41.5 54.8 64.3 75.8 8.7
Evidence of prior LMT 18.3 7.5 17.4 19.0 17.8 18.2 28.1
High-intensity statin 11.8 54.4 22.6 7.5 7.2 6.0 17.1
Low-to-moderate intensity statin 83.4 43.5 74.5 89.4 88.3 86.4 82.3
Nonstatin LMT 4.9 1.8 2.8 3.4 4.6 7.6 0.6
No evidence of prior LMT 28.4 7.9 14.5 24.0 40.3 39.3 7.2
ACS, acute coronary syndrome; ASCVD, atherosclerotic cardiovascular disease; CHD, coronary heart disease; DM, diabetes mellitus; HeFH, heterozygous familial hypercho-
lesterolemia; LMT, lipid-modifying therapy; PAD, peripheral arterial disease.
Numbers in the gray bars denote absolute percentages, and add up to 100% vertically. Numbers in the white bars are relative percentages of the absolute percentages in the
gray bars. ASCVD subgroups represent hierarchical categorization.
a HeFH includes primary prevention HeFH patients (no ASCVD) and secondary prevention HeFH patients (with ASCVD).
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non-statin LMT, prescribed in 91.3% of patients with HeFH receiving
non-statin LMT treatment. Regarding prior treatment for HeFH,
20.3% of HeFH patients without current LMT also had no evidence
of treatment in the 2-year period before the index date.3.2. ESC/EAS-recommended lipid goal achievement
In the overall cohort, mean (SD) LDL-C was 2.7 (1.0) mmol/l, and
16.0% and 45.0% achieved guideline-recommended LDL-C goals of
<1.8mmol/l and <2.5mmol/l, respectively. Mean (SD) non-HDL-C
M. Arca et al. / Atherosclerosis 271 (2018) 120e127124was 3.4 (1.1) mmol/l, with 24.3% achieving the <2.6mmol/l
threshold and 52.2% achieving the <3.3mmol/l threshold.
As expected, observed goal achievement was higher with high-
intensity than with low-to-moderate intensity statins (34.1% vs
23.0% for LDL-C <1.8mmol/l and 69.9% vs 61.3% for LDL-C
<2.5mmol/l; Table 3). Correspondingly, mean LDL-C and non-
HDL-C levels were lower for patients treated with high-intensity
versus low-to-moderate intensity statins (Supplemental Table 3).
Mean LDL-C and non-HDL-C levels were 2.9mmol/l and 3.7mmol/l
for patients receiving non-statin LMTand 3.1mmol/l and 3.7mmol/
l, respectively, among patients untreated on the index date.3.2.1. ASCVD population
Among all ASCVD risk conditions, mean LDL-C was lowest for
patients with recent ACS (2.1mmol/l), followed by CHD
(2.5mmol/l), stroke (2.8mmol/l), and PAD (2.9mmol/l). The
recent ACS group also had the highest proportion of LDL-C goal
achievers (42.7% for <1.8mmol/l and 76.2% for <2.5mmol/l),
followed by CHD (22.7% and 56.3%), stroke (12.7% and 40.8%), and
PAD (11.1% and 36.0%).
Mean non-HDL-C level was 2.6mmol/l in the recent ACS group,
3.1mmol/l in the CHD group, 3.4mmol/l for stroke, and 3.5mmol/l
for PAD. As with LDL-C, achievement of non-HDL-C goals was
highest among patients with recent ACS (55.1% for <2.6mmol/l and
80.1% for <3.3mmol/l), followed by CHD (32.9% and 62.3%) and
stroke (21.4% and 50.3%), and was lowest among PAD patientsTable 3
Achievement of lipid goals by CV risk category and treatment type.
% Total cohort
N¼ 66,158
ASCVD
n¼ 36,120
Recent ACS
n¼ 736
Chr
n¼
LDL-C<1.8mmol/l n¼ 10,573 n¼ 314 n¼
High-intensity statinb 34.1 52.3 36.1
Low-to-moderate intensity statinb 23.0 37.8 28.0
Nonstatin LMT only 10.0 7.1 12.5
No LMT at index date 6.8 20.4 8.4
LDL-C<2.5mmol/l n¼ 29,756 n¼ 561 n¼
High-intensity statinb 69.9 87.1 73.5
Low-to-moderate intensity statinb 61.3 75.5 68.3
Nonstatin LMT only 32.8 28.6 39.2
No LMT at index date 26.3 43.4 30.2
LDL-C≥2.5mmol/l n¼36,402 n¼ 175 n¼
High-intensity statinb 30.1 12.8 26.5
Low-to-moderate intensity statinb 38.7 24.5 31.7
Nonstatin LMT only 67.2 71.4 60.8
No LMT at index date 73.7 56.6 69.8
% Total cohort
N¼61,336c
ASCVD
n ¼ 33,510
Recent ACS
n¼668c
Chr
n¼1
Non-HDL-C <2.6mmol/l n¼ 14,891 n¼ 368 n¼
High-intensity statinb 44.4 63.9 46.7
Low-to-moderate intensity statinb 34.6 52.0 40.5
Nonstatin LMT only 12.7 7.1 17.9
No LMT at index date 12.1 34.3 15.3
Non-HDL-C<3.3mmol/l n¼ 32,012 n¼ 535 n¼
High-intensity statinb 74.2 89.4 77.2
Low-to-moderate intensity statinb 68.6 77.1 74.5
Nonstatin LMT only 36.3 35.7 39.7
No LMT at index date 34.3 56.9 37.6
ACS, acute coronary syndrome; ASCVD, atherosclerotic cardiovascular disease; CHD, coro
familial hypercholesterolemia; LDL-C, low-density lipoprotein cholesterol; LMT, lipid-m
ripheral arterial disease.
a HeFH includes primary prevention HeFH patients (no ASCVD) and secondary preven
b Statins in monotherapy and combination therapy.
c Non-HDL-C measurements were missing for a portion of each CV risk group.(18.3% and 45.6%).
Higher LDL-C and non-HDL-C goal achievement occurred with
more intensive statin treatment consistently across all ASCVD hi-
erarchical categories (Table 3).3.2.2. DM alone (non-ASCVD population)
Among patients with DM alone, mean LDL-C was 2.7mmol/l,
with 14.0% achieving LDL-C <1.8mmol/l and 42.9% achieving LDL-C
<2.5mmol/l. Mean non-HDL-C was 3.4mmol/l, and non-HDL-C
goals were attained by 21.3% of patients for <2.6mmol/l and
49.9% for <3.3mmol/l.
LDL-C goal achievement of <2.5mmol/l was similar among DM
patients receiving high-intensity and low-to-moderate intensity
statins; and likewise for non-HDL-C <3.3mmol/l threshold
achievement (Table 3).3.2.3. HeFH patients
Among patients with clinically diagnosed HeFH, mean LDL-C
was 5.4mmol/l, with less than 1% of patients achieving LDL-C
<1.8mmol/l and <2.5mmol/l. Mean non-HDL-C was 5.9mmol/l,
and proportions achieving non-HDL-C goals were likewise small
(1.1% and 2.3% for <2.6mmol/l and <3.3mmol/l, respectively). Due
to these low goal achievement rates, no differences by LMT use
were observed (Table 3).DM alone
n¼ 27,957
HeFHa
n¼ 2081
onic CHD
19,622
Stroke
n¼ 9721
PAD
n¼ 6041
4451 n¼ 1234 n¼ 670 n¼ 3902 n¼ 2
24.9 29.6 29.6 0
18.7 18.0 23.7 0.2
5.2 8.2 10.7 0
4.7 5.6 7.1 0
11,044 n¼ 3969 n¼ 2176 n¼ 12,004 n¼ 2
63.8 64.3 63.7 0
56.4 55.5 64.8 0.2
23.8 27.6 34.0 0
20.8 22.2 28.2 0
8578 n¼ 5752 n¼ 3865 n¼ 15,953 n¼ 2079
36.2 35.6 36.3 100
43.6 44.5 35.2 99.8
76.2 72.4 34.0 100
79.2 77.8 28.2 100
DM alone
n¼26,065c
HeFHa
n¼1,761c
onic CHD
8,218c
Stroke
n¼9001c
PAD
n¼5623c
5992 n¼ 1928 n¼ 1027 n¼ 5557 n¼ 19
34.1 38.0 39.8 3.4
31.1 28.9 34.9 0.8
9.2 5.6 11.9 0
9.5 10.7 12.1 1.1
11,349 n¼ 4528 n¼ 2562 n¼ 12,997 n¼ 41
69.2 66.0 70.6 3.4
66.4 65.5 71.1 2.2
30.8 36.0 37.8 0
30.5 32.0 35.7 2.5
nary heart disease; CV. cardiovascular; DM, diabetes mellitus; HeFH, heterozygous
odifying therapy; non-HDL-C, non-high-density lipoprotein cholesterol; PAD, pe-
tion HeFH patients (with ASCVD).
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Both the 2014 Italian national guidelines [19] and the ESC/EAS
guidelines [17,18] recommend that all patients at CV risk should
receive the highest-intensity statin needed to reach their target
LDL-C levels. This current study, conducted in a general practice
population in Italy at high or very-high risk for ASCVD events using
a large primary care EMR database, sought to provide additional
evidence regarding LMT utilization and lipid goal attainment in
Italy. Relative to other European countries, we observed low per-
centages of Italian patients who received any LMT (53.3%) while
being at high or very-high risk of CV events, thus confirming that
Italy remains a comparatively low user of statins despite compa-
rable CV risks. Another observation of the present study was the
low percentage of high-intensity statin users (7.7%), even for in-
dividuals classified as affected by severe genetic hypercholester-
olemia (e.g. HeFH) or in those at very-high CV risk. A possible
explanation may be related to the fact that the 2014 Italian national
guidelines strongly recommend use of low-to-moderate intensity
statin versus high-intensity statin as first prescription in untreated
patients.
Historically, overall statin use in Italy has grown significantly
over the past decade, including a nearly two-fold increase from
2004 to 2010 [25], irrespective of a restriction of reimbursement to
only high CV risk patients (defined as a 20% 10-year risk of a first
CV event, according to the CV risk chart of the Istituto Superiore di
Sanita [26], or established ASCVD or DM) by the Italian Medicine
Agency (Agenzia Italiana del Farmaco) in 2004 [27]. However, in
their 2013 analysis of healthmetrics, the Organisation for Economic
Co-operation and Development (OECD) found that Italy ranked
fifth-lowest among 23 member countries in terms of defined daily
dose of LMT per 1000 population, but 13th highest among 34
countries and above the OECD average for hospital discharges for
circulatory diseases per 1000 population. Italy is also 21st and 11th
for highest mortality among 33 countries related to ischemic heart
disease and cerebrovascular disease, respectively [28].
In the present study, the highest rate of statin usewas associated
with patients with a recent history of ACS (82.7%), and this is
consistent with previous publications [29,30]. Fewer ACS patients
in our study received high-intensity statins (56.1%) than those in
the studies by Maggioni et al. (84.9%) [29] and Degli Esposti et al.
(86.0%) [30], even though, with the patent for atorvastatin having
expired in November 2011, statins have since become much
cheaper for health services.
The proportion of CHD patients prescribed statins in our study
in 2015 (65.7%) was consistent with prescription rates after hospital
discharge in three earlier post-MI study cohorts [21,31e33]. A
subanalysis of PAD statistics in the multinational Prevalence of
peripheral Arterial disease in subjects with moderate CVD risk,
with No overt vascular Diseases nOR diAbetes mellitus (PANDORA)
study (2011) [34] showed very-low (6.5%) statin use in the Italian
PAD cohort compared with our finding of 40.3%.
The percentage of patients with DM prescribed statins in our
study (39.9%) has shown no change since a 2008 study by Modesti
et al. evaluating eight Italian primary care practices [35], which
predated the 2011 ESC/EAS guidelines, and in which only a third of
patients were prescribed statins. Despite the demonstrated benefit
of statins in DM patients, the post-MI study by Monaldi et al. [31]
found that the presence of DM significantly reduced the likelihood
of statin treatment both in hospital and at follow-up.
The aforementioned recommendation of the 2014 Italian na-
tional guidelines for use of low-to-moderate statin as first pre-
scriptionmight have contributed to the continuing low level of lipid
goal attainment observed in this cohort of Italian patients at high or
very-high CV risk. Overall, 55.0% were not at the less stringent ESC/EAS high CV risk LDL-C goal of <2.5mmol/l; despite the greater
probability of goal achievement with increasing statin intensity,
30.1% of patients taking high-intensity statins failed to achieve the
high CV risk LDL-C target and 65.9% failed to achieve the very-high
risk target (<1.8mmol/l). This is one of the few studies [36] that
measures non-HDL-C goal achievement in an Italian cohort. Over-
all, 52.2% had non-HDL-C levels <3.3mmol/l (ESC/EAS high CV risk
target) and 24.3% had non-HDL-C levels <2.6mmol/l (very-high CV
risk target).
Similar studies have been conducted in other European coun-
tries. The Spanish SAFEHEART Registry study found that 11.2% of
familial hypercholesterolemia patients achieved LDL-C<2.5mmol/l
despite 71.8% of patients being on maximal LMT; this number
increased to 22.4% over the 5-year follow-up [37]. In studies by
Pijlman et al. (Netherlands) [38] and Beliard et al. (France) [39],
LDL-C <2.5mmol/l was achieved in 20.9% and 10.4% of HeFH pa-
tients, respectively. In the latter study, the rate of goal achievement
with maximal LMT was 18.8%.
Our study's results are consistent with evidence of ESC/EAS goal
achievement seen in European statin data [15,16,40,41]. The Dys-
lipidemia International Study (DYSIS) [40], which evaluated LDL-C
goal achievement in European (n¼ 31,773) and Chinese
(n¼ 25,317) patients treated with statins, identified by EAS/ESC
criteria as being at very-high CV risk, found a 35.2% rate of goal
achievement (<1.8mmol/l) among the European cohort. Goal
achievement in EUROASPIRE IV (study data collected in
2014e2015) in all patients (86.0% on statins) was 19.3% for LDL-C
<1.8mmol/l and 57.8% for <2.5mmol/l [41]. Achievement for the
high-intensity and low-to-moderate intensity statin groups were
26.6% and 17.5%, respectively, for LDL-C <1.8mmol/l and 67.9% and
59.4%, respectively, for LDL-C <2.5mmol/l.
Statin underutilization is a multifactorial issue. For example,
reimbursement policy decisions have previously impacted con-
sumption of statins in Italy, as demonstrated by Damiani et al. [42].
As emphasized by an Italian intersociety position paper and in
several Italian studies, adherence is another fundamental element
of underutilization [43]. Statin intensity was identified byMaggioni
et al. [29] as a factor in adherence in a population of patients with
both ACS and DM. Adherence, defined by Maggioni et al. as the
correct daily dosage at 1-year follow-up, was increased with high-
intensity statin use versus low-to-moderate intensity statins (67.1%
vs 38.9%). However, since the data source in our study relies largely
on prescriptions, it was not possible to assess adherence in a sys-
tematic manner.
Strategies to maximize statin use in high CV risk patients are
critical to achieve the greatest possible reduction of CV outcomes.
Statins and non-statin LMT should be optimized to attain lipid
goals, such as those outlined in the ESC/EAS and other guidelines
[17]. Combination therapy with statins and ezetimibewas shown in
the IMProved Reduction of Outcomes: Vytorin Efficacy Interna-
tional Trial (IMPROVE-IT) study to reduce CV events in patients
with a recent ACS to a greater degree than statin alone [5]. New
classes of LMT are also emerging as therapeutic options in patients
at high CV risk. The European Medicines Agency has approved the
proprotein convertase subtilisin/kexin type 9 (PCSK9) inhibitors
alirocumab and evolocumab, which have been shown to lower LDL-
C by 50%e70% [44]; PCSK9 inhibitors have subsequently shown
cardiovascular benefits [45,46].
4.1. Limitations
As the study evaluated patients in primary care, results may not
be generalizable to high or very-high CV risk patients being treated
by a specialist. Secondly, the use of LMT was based on prescriptions
in the IMS Health Real World Data database, with which it is not
M. Arca et al. / Atherosclerosis 271 (2018) 120e127126possible to capture patient compliance. Thus, patients identified as
receiving LMT may not have been taking the prescribed treatment,
or taking it as prescribed. Thirdly, patient data were provided
voluntarily by GPs. GPs may have reached variable diagnoses,
which could have underestimated or misclassified patients in some
subgroups. Fourth, legitimate reasons for statin non-prescription,
such as intolerance or contraindication, were not identified.
Finally, patients were selected based on the availability of a lipid
measurement, which might not be representative of the total
population of Italian patients at high or very-high CV risk.
Sex disparities in LMT utilization and achievement of lipid goals
have been reported across a number of observational studies
[41,47,48], despite the similar efficacy of statins in men and women
observed in randomized clinical trials [49]. No sub-analyses by sex
were performed for the current dataset, thus this may also be
considered a limitation of this study.4.2. Conclusions
In summary, this large study shows that there continues to be
underutilization of LMTs among patients with high or very-high CV
risk in Italy, despite the demonstrated efficacy of statins in this
population. Optimal statin utilization, the addition of other LMTs
(such as ezetimibe and PCSK9 inhibitors), and patient adherence
programs may be expected to improve lipid goal achievement and
reduction in CV risk in this population. Such a shift towards better
lipid control in these individuals at high or very-high CV risk has
the potential to result in notable population health and pharma-
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